These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3486014)

  • 1. Identification of functional domains on von Willebrand factor by binding of tryptic fragments to collagen and to platelets in the presence of ristocetin.
    Houdijk WP; Schiphorst ME; Sixma JJ
    Blood; 1986 May; 67(5):1498-503. PubMed ID: 3486014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of distinct von Willebrand factor domains interacting with platelet GPIb and GPIIb/IIIa and with collagen using monoclonal antibodies.
    Girma JP; Kalafatis M; Piétu G; Lavergne JM; Chopek MW; Edgington TS; Meyer D
    Blood; 1986 May; 67(5):1356-66. PubMed ID: 3008890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tryptic fragments of von Willebrand factor involved in binding to thrombin-activated platelets with fragments involved in ristocetin-induced binding and binding to collagen.
    Houdijk WP; Girma JP; van Mourik JA; Sixma JJ; Meyer D
    Thromb Haemost; 1986 Dec; 56(3):391-6. PubMed ID: 3551182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen.
    Sixma JJ; Sakariassen KS; Stel HV; Houdijk WP; In der Maur DW; Hamer RJ; de Groot PG; van Mourik JA
    J Clin Invest; 1984 Sep; 74(3):736-44. PubMed ID: 6332119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin.
    Sixma JJ; Schiphorst ME; Verweij CL; Pannekoek H
    Eur J Biochem; 1991 Mar; 196(2):369-75. PubMed ID: 1901037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains.
    Tornai I; Arnout J; Deckmyn H; Peerlinck K; Vermylen J
    J Clin Invest; 1993 Jan; 91(1):273-82. PubMed ID: 8423224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib.
    Obert B; Houllier A; Meyer D; Girma JP
    Blood; 1999 Mar; 93(6):1959-68. PubMed ID: 10068669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of wheat germ agglutinin aggregation of platelets by von Willebrand protein and by a 116,000 molecular weight tryptic fragment.
    Martin SE; Francis CW; Marder VJ
    Thromb Res; 1983 Aug; 31(3):437-49. PubMed ID: 20218000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites.
    Mohri H; Yoshioka A; Zimmerman TS; Ruggeri ZM
    J Biol Chem; 1989 Oct; 264(29):17361-7. PubMed ID: 2477370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen. Effects of disulfide reduction and limited proteolysis of polymeric von Willebrand factor.
    Bockenstedt P; Greenberg JM; Handin RI
    J Clin Invest; 1986 Mar; 77(3):743-9. PubMed ID: 2936763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib.
    Girma JP; Takahashi Y; Yoshioka A; Diaz J; Meyer D
    Thromb Haemost; 1990 Oct; 64(2):326-32. PubMed ID: 1702906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of a recombinant glycoprotein Ib alpha polypeptide which inhibits von Willebrand factor binding to the platelet glycoprotein Ib-IX complex and to collagen.
    Cruz MA; Petersen E; Turci SM; Handin RI
    J Biol Chem; 1992 Jan; 267(2):1303-9. PubMed ID: 1730650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-collagen interaction: inhibition by ristocetin and enhancement by von Willebrand factor-platelet binding.
    LaDuca FM; Bettigole RE; Bell WR; Robson EB
    Blood; 1986 Oct; 68(4):927-37. PubMed ID: 3489493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
    De Luca M; Facey DA; Favaloro EJ; Hertzberg MS; Whisstock JC; McNally T; Andrews RK; Berndt MC
    Blood; 2000 Jan; 95(1):164-72. PubMed ID: 10607699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand factor. A protein which binds at the cell surface interface between platelets.
    Senogles SE; Nelsestuen GL
    J Biol Chem; 1983 Oct; 258(20):12327-33. PubMed ID: 6605342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib.
    Fujimura Y; Titani K; Holland LZ; Russell SR; Roberts JR; Elder JH; Ruggeri ZM; Zimmerman TS
    J Biol Chem; 1986 Jan; 261(1):381-5. PubMed ID: 2934387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
    Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
    Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence from limited proteolysis of a ristocetin-induced conformational change in human von Willebrand factor that promotes its binding to platelet glycoprotein Ib-IX-V.
    Kang M; Wilson L; Kermode JC
    Blood Cells Mol Dis; 2008; 40(3):433-43. PubMed ID: 17977030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-linking of a monomeric 39/34-kDa dispase fragment of von Willebrand factor (Leu-480/Val-481-Gly-718) to the N-terminal region of the alpha-chain of membrane glycoprotein Ib on intact platelets with bis(sulfosuccinimidyl) suberate.
    Andrews RK; Gorman JJ; Booth WJ; Corino GL; Castaldi PA; Berndt MC
    Biochemistry; 1989 Oct; 28(21):8326-36. PubMed ID: 2690940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.